Results 41 to 50 of about 30,900 (164)

A patient with maculopapular rash and lichenoid skin damage caused by ponatinib

Journal of International Medical Research, 2020
Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant ...
Ingrid Anna Teigen, Anna Kristine Myrmel Sæle, Håkon Reikvam   +2 more
doaj   +1 more source

Efficacy of Total‐Body Irradiation‐based Intensified Myeloablative Regimens for Acute Leukemia—An International Collaborative Study

eJHaem, Volume 6, Issue 3, June 2025.
ABSTRACT Background In this study, we compared outcomes of intensified myeloablative conditioning regimens using large registry data from Japan (Japanese Society for Transplantation and Cellular Therapy) and the United States (Center for International Blood and Marrow Transplant Research).
Yasuyuki Arai, Ruta Brazauskas, Naya He, A. Samer Al‐Homsi, Saurabh Chhabra, Minoo Battiwalla, Masamitsu Yanada, Amir Steinberg, Miguel Angel Diaz Perez, Sanghee Hong, Junya Kanda, Asad Bashey, Haydar A. Frangoul, Sherif M. Badawy, Leo F. Verdonck, Hillard M. Lazarus, Jean A. Yared, Hasan Hashem, Akshay Sharma, Mahmoud Aljurf, Ajoy L. Dias, Muhammad Bilal Abid, Baldeep Wirk, César O. Freytes, Amer M. Zeidan, Usama Gergis, Amer Beitinjaneh, Medhat Askar, Jeffrey J. Pu, Leslie E. Lehmann, Hemalatha G. Rangarajan, William A. Wood, Shahrukh Hashmi, Shingo Yano, Shinichi Kako, Yukiyasu Ozawa, Noriko Doki, Yoshinobu Kanda, Takahiro Fukuda, Yuta Katayama, Tatsuo Ichinohe, Junji Tanaka, Takanori Teshima, Shinichiro Okamoto, Yoshiko Atsuta, Wael Saber   +45 more
wiley   +1 more source

Ponatinib-associated panniculitis: Case report and review of the literature

Cancer Treatment and Research Communications, 2021
Ponatinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia. Common adverse effects of ponatinib include neutropenia, arterial thrombosis, and
Daniel Antwi-Amoabeng, Joban Ghuman, Jasmine Ghuman, Bryce D. Beutler, Mark B. Ulanja, Kevin Kuriakose, Aaron Bowman   +6 more
doaj  

Isorhamnetin 3-O-robinobioside from Nitraria retusa leaves enhance antioxidant and antigenotoxic activity in human chronic myelogenous leukemia cell line K562

BMC Complementary and Alternative Medicine, 2012
Background In this report, the isorhamnetin 3-o-robinobioside and its original extract, the ethyl acetate extract, from Nitraria retusa leaves, were evaluated for their ability to induce antioxidant and antigenotoxic effects in human chronic myelogenous ...
Boubaker Jihed, Sghaier Mohammed, Skandrani Ines, Ghedira Kamel, Chekir-Ghedira Leila   +4 more
doaj   +1 more source

Management of diffuse uterine leiomyomatosis for fertility preservation: Case series and systematic literature review

Journal of Obstetrics and Gynaecology Research, Volume 51, Issue 6, June 2025.
Abstract Aim The aim of this study was to evaluate the surgical, reproductive, and perinatal outcomes of patients with diffuse uterine leiomyomatosis desiring fertility preservation. Methods Patients diagnosed with diffuse uterine leiomyomatosis based on magnetic resonance imaging at Kindai University Hospital between 2017 and 2024 were included in a ...
Kiko Yamamoto, Kaoru Kawasaki, Kosuke Murakami, Yasushi Kotani, Noriomi Matsumura   +4 more
wiley   +1 more source

Novel clinical trial designs emerging from the molecular reclassification of cancer

CA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.
Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam, Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock   +4 more
wiley   +1 more source

Transcriptome sequencing of hematopoietic stem cells and chronic myelgenous leukemia stem cells

Genomics Data, 2016
Dipeptide species are accumulated in the chronic myelogenous leukemia (CML) stem cells [1]. To investigate the molecular mechanisms of the accumulation of dipeptide species in CML stem cells, we performed transcriptome sequencing of long-term stem cells,
Junil Kim, Seong-Jin Kim, Kazuhito Naka
doaj  

Autologous Peripheral Vγ9Vδ2 T Cell Synergizes with αβ T Cell Through Antigen Presentation and BTN3A1 Blockade in Immunotherapy of Cervical Cancer

Advanced Science, Volume 12, Issue 18, May 15, 2025.
This study provides proof‐of‐concept evidence showing that through direct killing, antigen presentation, and competitively binding to BTN3A1, Vγ9Vδ2 T cells amplified from cervical cancer (CC) patients can synergize with αβ T cells to exert anti‐CC function both in vitro and in vivo.
Min Wu, Jian Liu, Liting Liu, Yifan Yang, Hong Liu, Long Yu, Haihong Zeng, Shuo Yuan, Ruiyi Xu, Hangyu Liu, Han Jiang, Shen Qu, Liming Wang, Ying Chen, Jingyu Wang, Yuwei Zhang, Shan He, Ling Feng, Junyan Han, Wanjiang Zeng, Hui Wang, Yafei Huang   +21 more
wiley   +1 more source

HLA Class II Allele and Haplotype Frequencies in Iranian Patients with Leukemia

Iranian Journal of Allergy, Asthma and Immunology, 2007
Previous studies demonstrated significant differences in a number of HLA allele frequencies in leukemia patients and normal subjects. In this study, we have analyzed HLA class II alleles and haplotypes in 110 leukemia patients (60 acute myelogenous ...
Farideh Khosravi, Aliakbar Amirzargar, Abdolfatah Sarafnejad, Mohammad Hossein Nicknam, Kamran Alimoghadam, Saied Dianat, Ghasem Solgi, Behrouz Nikbin   +7 more
doaj  

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia

Oncology Reviews, 2011
Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have
Camillo Porta, Federica Tagliani
doaj   +1 more source